PD-L1 is not only a prognostic biomarker of immune therapy, but also a potential therapeutic target for glioblastoma [26], therefore, the unfavorable outcomes of this incurable tumor can significantly benefit from understanding the complex dynamics underlying PD-L1 expression regulation. Here, CD274 is linked to neoplasm.